New PAC Partners LBT report September 2018
Any thoughts!!!!!!! seems slow progress...
https://lbtinnovations.com/wp-content/uploads/News/Analyst-Coverage-Analyst-Report-PAC-Partners.pdf
INVESTMENT VIEW – Buy and 12 Month Price target$0.25/share. Long term DCF valuation of $0.44/share
• LBT sold its first unit last month, we estimate LBT will sellat least five units in FY’19F and 25 in FY’20F.• LBT is operating cash positive in 18 months, and will useits strong balance sheet for additional applications.
LBT Milestones & Risks
2HCY’18 – Evaluation trials in Australia pathology laboratorychain and German Labor Dictor Wisplinghoff pathology lab2HCY’18 – Two APAS® sales into Australia
1HCY’19 – Appointment of distributors in EU and US regions,and at least two APAS® into sales to EUCY’19 – US approval of supplementary 510(k) and extendAPAS® for different specimens and usesRISKS:
• Slow APAS® sales due to evaluation and approval
• Regulatory delays, and any issues with early users
RECOMMENDATION Buy
Previous Recommendation Initiating Coverage
Risk Rating Very High
Current Share Price $0.105
12 Month Price Target $0.25
Price Target Methodology
FY’21F EV/EBITDA 17xTotal Return (Capital + Yield) 138%
DCF Valuation $0.44Market capitalisation $25m
Liquidity – Daily Value $100k
PAC Partners September 2018 report
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
-0.001(5.56%) |
Mkt cap ! $23.13M | |||
| Open | High | Low | Value | Volume |
| 1.8¢ | 1.8¢ | 1.7¢ | $13.20K | 747.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 776749 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 238095 | 1 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| LBT (ASX) Chart |
Day chart unavailable
